13-Valent pneumococcal conjugate vaccine
13-Valent pneumococcal conjugate vaccine is a biological therapy with 45 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 43 completed trials
Phase Distribution
Phase Distribution
4
Early Stage
4
Mid Stage
36
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
100.0%
43 of 43 finished
0.0%
0 ended early
0
trials recruiting
45
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Phase I/II Clinical Trial of 26-valent Pneumococcal Conjugate Vaccine
A Study to Describe the Safety and Immunogenicity of 20vPnC in Infants in India and Taiwan
A Phase I Clinical Study to Evaluate the Safety of PCV26 in Individuals ≥60
A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age
Safety and Immunogenicity of 20vPnC in Toddlers With 2 Prior Doses of Prevenar 13
Clinical Trials (45)
Phase I/II Clinical Trial of 26-valent Pneumococcal Conjugate Vaccine
A Study to Describe the Safety and Immunogenicity of 20vPnC in Infants in India and Taiwan
A Phase I Clinical Study to Evaluate the Safety of PCV26 in Individuals ≥60
A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age
Safety and Immunogenicity of 20vPnC in Toddlers With 2 Prior Doses of Prevenar 13
A Study to Describe the Safety of a Vaccine (Called 13vPnC) in Healthy People 18 to 49 Years of Age in India
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants
20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Healthy Japanese Infants
Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease
A Phase III Clinical Trial of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants
Immunogenicity and Safety Study of 15-Valent Pneumococcal Conjugate Vaccine in 2-month-old and 3-month-old Healthy Volunteers
A Safety And Immunogenicity Study Of A 13-valent Pneumococcal Conjugate Vaccine In Japanese Subjects Aged 6 To 64 Years.
PCV13 in Non-pregnant Papua New Guinean Women
A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Subjects
Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Preterm Compared to Term Infants.
13-valent Pneumococcal Conjugate Vaccine Study in Adults and Children in India
Concomitant Administration of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) With Influenza Vaccine in 23-valent Pneumococcal Polysaccharide (23vPS) Pre-vaccinated Adults.
An Alternative Booster Vaccine Against Meningitis and Ear Infections
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 45